RWA Wealth Partners LLC Has $58.61 Million Position in AbbVie Inc. $ABBV

RWA Wealth Partners LLC decreased its position in AbbVie Inc. (NYSE:ABBV) by 6.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 253,128 shares of the company’s stock after selling 18,851 shares during the quarter. AbbVie makes up approximately 0.7% of RWA Wealth Partners LLC’s portfolio, making the stock its 23rd largest holding. RWA Wealth Partners LLC’s holdings in AbbVie were worth $58,609,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of the company. Diversified Trust Co grew its holdings in AbbVie by 23.6% in the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after buying an additional 10,891 shares during the last quarter. Permanent Capital Management LP acquired a new position in shares of AbbVie during the third quarter worth approximately $720,000. Railway Pension Investments Ltd boosted its position in shares of AbbVie by 33.0% in the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock valued at $197,723,000 after acquiring an additional 211,800 shares during the period. World Investment Advisors grew its stake in shares of AbbVie by 9.4% in the third quarter. World Investment Advisors now owns 113,925 shares of the company’s stock worth $26,378,000 after acquiring an additional 9,811 shares during the last quarter. Finally, Charles Schwab Trust Co increased its position in AbbVie by 93.4% during the third quarter. Charles Schwab Trust Co now owns 32,105 shares of the company’s stock worth $7,434,000 after acquiring an additional 15,502 shares during the period. 70.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Piper Sandler increased their price target on shares of AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a report on Wednesday, February 18th. Morgan Stanley upped their price objective on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Raymond James Financial set a $256.00 target price on shares of AbbVie in a research note on Monday, November 3rd. DZ Bank cut AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target for the company. in a report on Tuesday, November 4th. Finally, Citigroup reduced their price objective on AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research report on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Stock Down 0.5%

Shares of ABBV opened at $228.44 on Wednesday. The company has a 50-day moving average price of $224.17 and a two-hundred day moving average price of $222.67. The stock has a market cap of $403.92 billion, a price-to-earnings ratio of 96.80, a P/E/G ratio of 0.80 and a beta of 0.35. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.AbbVie’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is presently 293.22%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Announced a $380 million investment to build two active pharmaceutical ingredient (API) plants at its North Chicago campus to support neuroscience and obesity medicines; construction starts spring 2026 and facilities are expected online by 2029, strengthening domestic supply and “Made in U.S.” manufacturing capacity. Article Title
• Positive Sentiment: FDA approved the combination of VENCLEXTA (venetoclax) and acalabrutinib as a first-line, all‑oral, fixed‑duration regimen for previously untreated CLL — a label expansion that can meaningfully support oncology revenue growth. Article Title
• Positive Sentiment: Barclays initiated coverage with an Overweight rating and $275 price target, citing upside from operating leverage and under‑appreciated growth potential — a catalyst that can attract buyers. Article Title
• Neutral Sentiment: AbbVie completed a real‑world study of Vraylar in bipolar I disorder, a data point that supports the product’s real‑world evidence but is unlikely to move near‑term revenue materially. Article Title
• Neutral Sentiment: Analysts have modestly updated fair‑value models (example: a small move to ~$248.29), reflecting mixed views — positive readthroughs on pipeline and immunology assets offset by caution on execution. Article Title
• Negative Sentiment: Investor concerns about competitive pressure in key franchises and execution risk (integration, manufacturing ramp timelines, and maintaining growth after major product lifecycles) are being highlighted in coverage and may be prompting profit‑taking. Article Title

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.